Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer
By:
References
- WHO (2023). Lung cancer. https://www.who.int/news-room/fact-sheets/detail/lung-cancer
- Sung H., Ferlay J., Siegel R.L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3): 209–249. doi:
10.3322/caac.21660 . - Society A.C. (2019). Key Statistics for Lung Cancer, https://www.cancer.org/content/cancer/en/cancer/non-small-cell-lung-cancer/about/key-statistics/.
- Borghaei H., Paz-Ares L., et al. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med; 373(17): 1627–1639. doi:
10.1056/NEJMoa1507643 . - Gettinger S., Rizvi N.A., et al. (2016). Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol; 34(25): 2980–2987. doi:
10.1200/JCO.2016.66.9929 . - Han Y., Liu D. and Li L. (2020). PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10(3): 727–742. PMCID:
PMC7136921 . - Sun C, Mezzadra R, Schumacher TN. (2018). Regulation and Function of the PD-L1 Checkpoint. Immunity (2018) 48:434–52. doi:
10.1016/j.immuni.2018.03.014 . - Guixiang Liao, Zhihong Zhao, Yuting Qian, et al. (2021). Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11: 774131. doi:
10.3389/fonc.2021.774131 - Cui S, Su X, Dong L, Qian J, et al. (2017). Programmed Cell Death Ligand 1 Protein Levels Predicted Survival of Non-Small Cell Lung Cancer. J Cancer (2017) 8:4075–82. doi:
10.7150/jca.21415 . - Ishii H., Azuma K., Kawahara A., et al. (2015). Significance of Programmed Cell Death - Ligand 1 Expression and its Association With Survival in Patients With Small Cell Lung Cancer. J Thorac Oncol (2015) 10:426–30. doi:
10.1097/JTO.0000000000000414 - SoYeon Oh, Soyeon Kim, Bhumsuk Keam, et al. (2021). Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021 Oct 5;11(1):19712. doi:
10.1038/s41598-021-99311-y - Rami-Porta R., Bolejack V., Crowley J., et al. (2015). The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 10(7): 990–1003. doi:
10.1097/JTO.0000000000000559 . - Travis W.D., Brambilla E., Nicholson A.G., et al. (2015). The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol, 10(9): 1243–1260. doi:
10.1097/JTO.0000000000000630 . - Teixido C., Vilarino N., Reyes R., et al. (2018). PD-L1 expression testing in non-small cell lung cancer. Ther Adv Med Oncol, 10: 1758835918763493.
- Corp. C.-C., Instruction manual, SEA788Hu 96 Tests Enzyme-linked Immunosorbent Assay Kit For Programmed Cell Death Protein 1 Ligand 1 (PDCD1LG1) Organism Species: Homo sapiens (Human).
- Chuling Li, Chuwei Li, Chunchun Zhi, et al. (2019). Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. Journal of Translational Medicine Vol. 17, 355 (2019).
- Yumin Wu, Hui Guo, Jiawei Yue (2022). Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients. Journal of Immunology Research. Vol 2022. doi:
10.1155/2022/9101912 - Borghaei H., Paz-Ares L., Horn L., et al. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 373(17): 1627–1639. doi:
10.1056/NEJMoa1507643 . - Brahmer J., Reckamp K.L., Baas P., et al. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 373(2): 123–135. doi:
10.1056/NEJMoa1507643 . - Gettinger S., Rizvi N.A., Chow L.Q., et al. (2016). Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 34(25): 2980–2987. doi:
10.1200/JCO.2016.66.9929 . - Hellmann M.D., Ciuleanu T.E., Pluzanski A., et al. (2018). Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med, 378(22): 2093–2104. doi:
10.1056/NEJMoa1801946 . - Gandhi L., Rodriguez-Abreu D., Gadgeel S., et al. (2018). Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med, 378(22): 2078–2092. doi:
10.1056/NEJMoa1801005 . - Garon E.B., Rizvi N.A., Hui R., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med, 372(21): 2018–2028. doi:
10.1056/NEJMoa1501824 . - Herbst R.S., Baas P., Kim D.W., et al. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387(10027): 1540–1550. doi:
10.1016/S0140-6736(15)01281-7 . - Gubens M.A., Sequist L.V., Stevenson J.P., et al. (2019). Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer, 130: 59–66. doi:
10.1016/j.lungcan.2018.12.015 . - Mok T.S.K., Wu Y.L., Kudaba I., et al. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 393(10183): 1819–1830. doi:
10.1016/S0140-6736(18)32409-7 . - Reck M., Rodriguez-Abreu D., Robinson A.G., et al. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 375(19): 1823–1833. doi:
10.1056/NEJMoa1606774 . - Fehrenbacher L., Spira A., Ballinger M., et al. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387(10030): 1837–1846. doi:
10.1016/S0140-6736(16)00587-0 . - Verschraegen C.F., Jerusalem G., McClay E.F., et al. (2020). Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. J Immunother Cancer, 8(2): e001064. doi:
10.1136/jitc-2020-001064 . - Barlesi F., Vansteenkiste J., Spigel D., et al. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. The Lancet. Oncology, 19(11): 1468–1479. doi:
10.1016/S1470-2045(18)30673-9 . - Giuseppe Lamberti, Monia Sisi, Elisa Andrini, et al. (2020). The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?. Cancers (Basel). 2020 Nov; 12(11): 3129. doi:
10.3390/cancers12113129 . - P Song, S Wu, L Zhang, X Zeng, et al. (2019). Correlation between PD-L1 expression and clinicopathologic features in 404 patients with lung adenocarcinoma. Interdisciplinary Sciences: Computational Life Sciences, Vol. 11, 258–265. doi:
10.1007/s12539-019-00329-8 . - Zhu X., Lang J. Soluble PD-1 and PD-L1: Predictive and prognostic significance in cancer. Oncotarget. 2017;8:97671–97682. doi:
10.18632/oncotarget.18311 . - Christian Bailly, Xavier Thuru, and Bruno Quesnel (2021). Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel). 2021 Jun; 13(12): 3034. doi:
10.3390/cancers13123034 . - Khan M., Zhao Z., Arooj S., et al. (2020). Soluble PD-1: Predictive, prognostic, and therapeutic value for cancer immunotherapy. Front. Immunol. 2020;11:587460. doi:
10.3389/fimmu.2020.587460 . - Zhang J., Gao J., Li Y., et al. (2015). Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer, 6(4): 534–538. doi:
10.1111/1759-7714.12247 . - Okuma Y., Hosomi Y., Nakahara Y., et al. (2017). High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer, 104: 1–6. doi:
10.1016/j.lungcan.2016.11.023 . - Costantini A., Julie C., Dumenil C., et al. (2018). Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology, 7(8): e1452581. doi:
10.1080/2162402X.2018.1452581 . - Murakami S., Shibaki R., Matsumoto Y., et al. (2020). Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Thorac Cancer, 11(12): 3585–3595. doi:
10.1111/1759-7714.13721 . - Yumin Wu, Hui Guo, Jiawei Yue, et al. (2022). Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients. Journal of Immunology Research, Volume 2022, Article ID 9101912, doi.org/10.1155/2022/9101912.
Language: English
Page range: 36 - 44
Submitted on: May 19, 2024
Accepted on: Aug 2, 2024
Published on: Nov 10, 2024
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Related subjects:
© 2024 Thang Ba Ta, Nhung Thi Kim Pham, Dung Tien Nguyen, Tien Viet Tran, Cuong Tan Tran, Thuc Cong Luong, Hoan Ngoc Vu, Hien Thi Dieu Le, Bang Ngoc Dao, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.